Clinical trials: Germ Cell Neoplasm
Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
Nivolumab (OpdivoTM, BMS), a human IgG-4 anti-PD-1 monoclonal antibody has demonstrated anti-tumor activity in patients with advanced melanoma.
- Trial name
- ipniv (NCT02941744)
- Testing
- nivolumab, ipilimumab
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Melanoma, Dysplastic Nevus Syndrome
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions.
- Trial name
- NCT00040352
- Where
- 2 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Pheochromocytoma, Paraganglioma
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous.
- Conditions
- Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome, Associated Conditions
- Trial name
- NCT03160274
- Testing
- Genetic screening
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Autonomic Nervous System Disease, Healthy
Blood Sampling for Neurochemical and Genetic Testing
This study involves sampling blood from both normal volunteers and patients with diseases known or suspected to involve body chemicals called catecholamines.
- Conditions
- Autonomic Nervous System Disease, Healthy, Hypertension, Pheochromocytoma
- Trial name
- NCT00001147
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Glioma
Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in…
- Trial name
- NCT04217044
- Testing
- Histopathology images based prediction of molecular pathology
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Glioma, Glioblastoma Multiforme
Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients
This is an exploratory, non-interventional and translational clinical study. The aim of this study is to analyze blood and cerebrospinal fluid metabolomic profile in glioma patients.
- Trial name
- NCT03865355
- Testing
- Non- interventional
- Where
- Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novosibirsk State University
Melanoma, Skin Cancer
Integrated Basic Science Within the Instructional Design of Pattern Recognition Training
Investigators hypothesize that the introduction of basic science explanations within the instructional design of case-based training in visual diagnostics will improve students' learning curves, retention, and retrieval of…
- Trial name
- AISC-ISF (NCT05087485)
- Testing
- education
- Where
- Denmark
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Neuroendocrine Neoplasm
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ） positron emission tomography / computed tomography (PET/CT) in…
- Trial name
- NCT03511768
- Testing
- 18F-AlF-NOTA-octreotide, PET/CT
- Where
- China
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Melanoma
LATe TreatmENT Related Toxicity in Melanoma (LATENT)
Recent improvements in advanced melanoma treatment with immunotherapy have dramatically improved patient survival. Longer survival however has come at a cost of toxicity.
- Trial name
- LATENT (NCT06414343)
- Testing
- Observational - no intervention
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust